Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Company Overview

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.04
• 52-Week Range: $0.02 to $16.25
• Volume: 260,246 shs
• Average Volume: 4.98 million shs
• Market Capitalization: $856.90 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTPI Stock Analysis - Frequently Asked Questions

How have PTPI shares performed this year?

Petros Pharmaceuticals' stock was trading at $9.8475 at the start of the year. Since then, PTPI shares have decreased by 99.7% and is now trading at $0.0275.

How were Petros Pharmaceuticals' earnings last quarter?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($8.46) earnings per share for the quarter.

When did Petros Pharmaceuticals' stock split?

Shares of Petros Pharmaceuticals reverse split on the morning of Thursday, May 1st 2025.The 1-25 reverse split was announced on Tuesday, April 29th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Petros Pharmaceuticals?

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Petros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PTPI
• CIK: 1815903
• Web: www.petrospharma.com
• Phone: 973-242-0005
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($52.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.16 million
• Net Margins: N/A
• Pretax Margin: -117.50%
• Return on Equity: -78.22%
• Return on Assets: -23.50%

Debt

• Debt-to-Equity Ratio: 1.58
• Current Ratio: 0.85
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: $5.11 million
• Price / Sales: 0.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 31,160,000
• Free Float: 9,932,000
• Market Cap: $856.90 thousand
• Optionable: Not Optionable
• Beta: 1.56